Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherTheranostics

Early prostate-specific antigen changes and clinical outcome following 177Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer

Andrei Gafita, Matthias Heck, Isabel Rauscher, Robert Tauber, Lisena Cala, Charlott Franz, Calogero D'Alessandria, Margitta Retz, Wolfgang Andreas Weber and Matthias Eiber
Journal of Nuclear Medicine February 2020, jnumed.119.240242; DOI: https://doi.org/10.2967/jnumed.119.240242
Andrei Gafita
1 Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Heck
2 Department of Urology, Technical University Munich, Klinikum rechts der Isar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabel Rauscher
1 Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Tauber
2 Department of Urology, Technical University Munich, Klinikum rechts der Isar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisena Cala
1 Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlott Franz
1 Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Calogero D'Alessandria
1 Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margitta Retz
1 Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang Andreas Weber
1 Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Eiber
1 Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Data supplements

  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 66 (5)
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Early prostate-specific antigen changes and clinical outcome following 177Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Early prostate-specific antigen changes and clinical outcome following 177Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer
Andrei Gafita, Matthias Heck, Isabel Rauscher, Robert Tauber, Lisena Cala, Charlott Franz, Calogero D'Alessandria, Margitta Retz, Wolfgang Andreas Weber, Matthias Eiber
Journal of Nuclear Medicine Feb 2020, jnumed.119.240242; DOI: 10.2967/jnumed.119.240242

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Early prostate-specific antigen changes and clinical outcome following 177Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer
Andrei Gafita, Matthias Heck, Isabel Rauscher, Robert Tauber, Lisena Cala, Charlott Franz, Calogero D'Alessandria, Margitta Retz, Wolfgang Andreas Weber, Matthias Eiber
Journal of Nuclear Medicine Feb 2020, jnumed.119.240242; DOI: 10.2967/jnumed.119.240242
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Initial Experience with [177Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction
  • Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection
  • Google Scholar

More in this TOC Section

Theranostics

  • Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
  • Determination of the Intralesional Distribution of Theranostic 124I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
Show more Theranostics

Clinical (Oncology: GU)

  • Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
  • A Comparison of 18F-DCFPyL, 18F-NaF, and 18F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer
  • Detection of Additional Primary Neoplasms on 18F-Fluciclovine PET/CT in Patients with Primary Prostate Cancer
Show more Clinical (Oncology: GU)

Similar Articles

Keywords

  • Oncology: GU
  • PET/CT
  • radionuclide therapy
  • LuPSMA
  • PSA
  • PSMA
  • prostate cancer
SNMMI

© 2025 SNMMI

Powered by HighWire